Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revision Previous revision
Last revision Both sides next revision
epilepsy [2018/11/18 10:57]
sflitman [Epilepsy and Seizure Disorders]
epilepsy [2018/11/18 10:58]
sflitman [Epilepsy and Seizure Disorders]
Line 8: Line 8:
  
 ^ Condition(s) ^ Type of Drug ^ Phase ^ Add-On ^ Placebo ^ Duration ^ Open Label Extension ^ ^ Condition(s) ^ Type of Drug ^ Phase ^ Add-On ^ Placebo ^ Duration ^ Open Label Extension ^
-| Partial Seizures |  Novel oral agent  |  II |  Yes  |  ​50%  |  ​1 year  ​| ​ To market ​ |+| Partial Seizures |  Novel oral agent  |  II |  Yes  |  ​20%  |  ​20 weeks  ​| ​ To market ​ |
 | Partial Seizures |  Intravenous Natalizumab ​ |  II  |  Yes  |  50%  |  6 months ​ |   6 months ​ | | Partial Seizures |  Intravenous Natalizumab ​ |  II  |  Yes  |  50%  |  6 months ​ |   6 months ​ |
  
Print/export
QR Code
QR Code epilepsy (generated for current page)